The cost of haste: On drugs, vaccines and regulators

So significant are the impacts of COVID-19 that it has harried drug regulative authorities, generally the most risk-averse within the bureaucracy. ‘Do no damage’ is the driving principle of drug policy and this is reflected in the thicket of files and consents that stand prior to the typical novel drug or vaccine, for a chance at making it to the marketplace. SARS-CoV-2, while primarily non-lethal, eliminates throughout demography and age-groups to confound advanced care systems. This has actually sent out a signal to drug companies, biomedical companies and federal governments to rush for anything with even the tiniest possibility of success. It is in this context that regulators, utilized to long timelines of checking brand-new vaccines or drugs, are now under pressure to facilitate an option rather than adhere to weighing and residence on evidence of effectiveness and security. India’s drug regulatory authority in addition to the Department of Biotechnology, which also funds vaccine development and drug research, now collaborate on